Search

Your search keyword '"van de Wijgert, Janneke H. H. M."' showing total 305 results
Start Over Author "van de Wijgert, Janneke H. H. M."
305 results on '"van de Wijgert, Janneke H. H. M."'

4. Head-to-head comparison of the accuracy of saliva and nasal rapid antigen SARS-CoV-2 self-testing: cross-sectional study

Author

Schuit, Ewoud, Venekamp, Roderick P., Veldhuijzen, Irene K., van den Bijllaardt, Wouter, Pas, Suzan D., Stohr, Joep J. J. M., Lodder, Esther B., Hellwich, Marloes, Molenkamp, Richard, Igloi, Zsofia, Wijers, Constantijn, Vroom, Irene H., Nagel-Imming, Carla R. S., Han, Wanda G. H., Kluytmans, Jan A. J. W., van den Hof, Susan, van de Wijgert, Janneke H. H. M., and Moons, Karel G. M.

Published
2022
Full Text
View/download PDF

5. Detection of SARS-CoV-2 infection in the general population by three prevailing rapid antigen tests: cross-sectional diagnostic accuracy study

Author

Venekamp, Roderick P., Veldhuijzen, Irene K., Moons, Karel G. M., van den Bijllaardt, Wouter, Pas, Suzan D., Lodder, Esther B., Molenkamp, Richard, Igloi, Zsofi, Wijers, Constantijn, dos Santos, Claudy Oliveira, Debast, Sylvia B., Bruins, Marjan J., Polad, Khaled, Nagel-Imming, Carla R. S., Han, Wanda G. H., van de Wijgert, Janneke H. H. M., van den Hof, Susan, and Schuit, Ewoud

Published
2022
Full Text
View/download PDF

6. Novel point-of-care cytokine biomarker lateral flow test for the screening for sexually transmitted infections and bacterial vaginosis: study protocol of a multicentre multidisciplinary prospective observational clinical study to evaluate the performance and feasibility of the Genital InFlammation Test (GIFT)

Author

Ramboarina, Stephanie, primary, Crucitti, Tania, additional, Gill, Katherine, additional, Bekker, Linda Gail, additional, Harding-Esch, Emma Michele, additional, van de Wijgert, Janneke H H M, additional, Huynh, Bich-Tram, additional, Fortas, Camille, additional, Harimanana, Aina, additional, Mayouya Gamana, Théodora, additional, Randremanana, Rindra Vatosoa, additional, Mangahasimbola, Reziky, additional, Dziva Chikwari, Chido, additional, Kranzer, Katharina, additional, Mackworth-Young, Constance R S, additional, Bernays, Sarah, additional, Thomas, Nicola, additional, Anderson, David, additional, Tanko, Fatime Ramla, additional, Manhanzva, Monalisa, additional, Lurie, Micaela, additional, Khumalo, Fezile, additional, Sinanovic, Edina, additional, Honda, Ayako, additional, Pidwell, Tanya, additional, Francis, Suzanna C, additional, Masson, Lindi, additional, and Passmore, Jo-Anne, additional

Published
2024
Full Text
View/download PDF

7. High adherence to intermittent and continuous use of a contraceptive vaginal ring among women in a randomized controlled trial in Kigali, Rwanda

Author

Kestelyn, Evelyne, primary, Van Nuil, Jennifer Ilo, additional, Umulisa, Marie Michelle, additional, Umutoni, Grace, additional, Uwingabire, Alice, additional, De Baetselier, Irith, additional, Uwineza, Mireille, additional, Agaba, Stephen, additional, Crucitti, Tania, additional, Delvaux, Thérèse, additional, and van de Wijgert, Janneke H. H. M., additional

Published
2024
Full Text
View/download PDF

8. Health-related quality of life during the COVID-19 pandemic: The impact of restrictive measures using data from two Dutch population-based cohort studies

Author

van Hagen, Cheyenne C. E., primary, Huiberts, Anne J., additional, Mutubuki, Elizabeth N., additional, de Melker, Hester E., additional, Vos, Eric R. A., additional, van de Wijgert, Janneke H. H. M., additional, van den Hof, Susan, additional, Knol, Mirjam J., additional, and van Hoek, Albert Jan, additional

Published
2024
Full Text
View/download PDF

9. Within-episode repeat antibiotic prescriptions in patients with respiratory tract infections: A population-based cohort study

Author

Lalmohamed, Arief, Venekamp, Roderick P, Bolhuis, Albert, Souverein, Patrick C, van de Wijgert, Janneke H H M, Gulliford, Martin C, Hay, Alastair D, Lalmohamed, Arief, Venekamp, Roderick P, Bolhuis, Albert, Souverein, Patrick C, van de Wijgert, Janneke H H M, Gulliford, Martin C, and Hay, Alastair D

Abstract

Background: Antimicrobial stewardship interventions mainly focus on initial antibiotic prescriptions, with few considering within-episode repeat prescriptions. We aimed to describe the magnitude, type and determinants of within-episode repeat antibiotic prescriptions in patients presenting to primary care with respiratory tract infections (RTIs). Methods: We conducted a population-based cohort study among 530 sampled English general practices within the Clinical Practice Research Datalink (CPRD). All individuals with a primary care RTI consultation for which an antibiotic was prescribed between March 2018 and February 2022. Main outcome measurement was repeat antibiotic prescriptions within 28 days of a RTI visit stratified by age (children vs. adults) and RTI type (lower vs. upper RTI). Multivariable logistic regression and principal components analyses were used to identify risk factors and patient clusters at risk for within-episode repeat prescriptions. Findings: 905,964 RTI episodes with at least one antibiotic prescription were identified. In adults, 19.9% (95% CI 19.3–20.5%) had at least one within-episode repeat prescription for a lower RTI, compared to 10.5% (95% CI 10.3–10.8%) for an upper RTI. In children, this was around 10% irrespective of RTI type. The majority of repeat prescriptions occurred a median of 10 days after the initial prescription and was the same antibiotic class in 48.3% of cases. Frequent RTI related GP visits and prior within-RTI-episode repeat antibiotic prescriptions were main factors associated with repeat prescriptions in both adults and children irrespective of RTI type. Young (<2 years) and older (65+) age were associated with repeat prescriptions. Among those aged 2–64 years, allergic rhinitis, COPD and oral corticosteroids were associated with repeat prescriptions. Interpretations: Repeat within-episode antibiotic use accounts for a significant proportion of all antibiotics prescribed for RTIs, with same class antibiotics

Published
2024

10. Determinants of Systemic SARS-CoV-2-Specific Antibody Responses to Infection and to Vaccination: A Secondary Analysis of Randomised Controlled Trial Data

Author

Infection & Immunity, Epi Infectieziekten Team 1b, Epi Infectieziekten Team 1, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, Claus, Juana, Ten Doesschate, Thijs, Taks, Esther, Debisarun, Priya A, Smits, Gaby, van Binnendijk, Rob, van der Klis, Fiona, Verhagen, Lilly M, de Jonge, Marien I, Bonten, Marc J M, Netea, Mihai G, van de Wijgert, Janneke H H M, Infection & Immunity, Epi Infectieziekten Team 1b, Epi Infectieziekten Team 1, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectieziekten, Claus, Juana, Ten Doesschate, Thijs, Taks, Esther, Debisarun, Priya A, Smits, Gaby, van Binnendijk, Rob, van der Klis, Fiona, Verhagen, Lilly M, de Jonge, Marien I, Bonten, Marc J M, Netea, Mihai G, and van de Wijgert, Janneke H H M

Published
2024

11. Health-related quality of life during the COVID-19 pandemic: The impact of restrictive measures using data from two Dutch population-based cohort studies

Author

Epi Infectieziekten Team 1b, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, van Hagen, Cheyenne C E, Huiberts, Anne J, Mutubuki, Elizabeth N, de Melker, Hester E, Vos, Eric R A, van de Wijgert, Janneke H H M, van den Hof, Susan, Knol, Mirjam J, van Hoek, Albert Jan, Epi Infectieziekten Team 1b, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, van Hagen, Cheyenne C E, Huiberts, Anne J, Mutubuki, Elizabeth N, de Melker, Hester E, Vos, Eric R A, van de Wijgert, Janneke H H M, van den Hof, Susan, Knol, Mirjam J, and van Hoek, Albert Jan

Published
2024

12. High adherence to intermittent and continuous use of a contraceptive vaginal ring among women in a randomized controlled trial in Kigali, Rwanda

Author

Epi Infectieziekten Team 1b, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Kestelyn, Evelyne, Van Nuil, Jennifer Ilo, Umulisa, Marie Michelle, Umutoni, Grace, Uwingabire, Alice, De Baetselier, Irith, Uwineza, Mireille, Agaba, Stephen, Crucitti, Tania, Delvaux, Thérèse, van de Wijgert, Janneke H H M, Epi Infectieziekten Team 1b, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Kestelyn, Evelyne, Van Nuil, Jennifer Ilo, Umulisa, Marie Michelle, Umutoni, Grace, Uwingabire, Alice, De Baetselier, Irith, Uwineza, Mireille, Agaba, Stephen, Crucitti, Tania, Delvaux, Thérèse, and van de Wijgert, Janneke H H M

Published
2024

13. Within-episode repeat antibiotic prescriptions in patients with respiratory tract infections: A population-based cohort study

Author

Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Pharmacoepidemiology and Clinical Pharmacology, Lalmohamed, Arief, Venekamp, Roderick P, Bolhuis, Albert, Souverein, Patrick C, van de Wijgert, Janneke H H M, Gulliford, Martin C, Hay, Alastair D, Afd Pharmacoepi & Clinical Pharmacology, PECP - Centre for Pharmacoepidemiology, Pharmacoepidemiology and Clinical Pharmacology, Lalmohamed, Arief, Venekamp, Roderick P, Bolhuis, Albert, Souverein, Patrick C, van de Wijgert, Janneke H H M, Gulliford, Martin C, and Hay, Alastair D

Published
2024

14. Determinants of Systemic SARS-CoV-2-Specific Antibody Responses to Infection and to Vaccination: A Secondary Analysis of Randomised Controlled Trial Data.

Author

Claus, Juana, ten Doesschate, Thijs, Taks, Esther, Debisarun, Priya A., Smits, Gaby, van Binnendijk, Rob, van der Klis, Fiona, Verhagen, Lilly M., de Jonge, Marien I., Bonten, Marc J. M., Netea, Mihai G., and van de Wijgert, Janneke H. H. M.

Subjects
MEDICAL personnel, ANTIBODY formation, RANDOMIZED controlled trials, POST-acute COVID-19 syndrome, COVID-19
Abstract

SARS-CoV-2 infections elicit antibodies against the viral spike (S) and nucleocapsid (N) proteins; COVID-19 vaccines against the S-protein only. The BCG-Corona trial, initiated in March 2020 in SARS-CoV-2-naïve Dutch healthcare workers, captured several epidemic peaks and the introduction of COVID-19 vaccines during the one-year follow-up. We assessed determinants of systemic anti-S1 and anti-N immunoglobulin type G (IgG) responses using trial data. Participants were randomised to BCG or placebo vaccination, reported daily symptoms, SARS-CoV-2 test results, and COVID-19 vaccinations, and donated blood for SARS-CoV-2 serology at two time points. In the 970 participants, anti-S1 geometric mean antibody concentrations (GMCs) were much higher than anti-N GMCs. Anti-S1 GMCs significantly increased with increasing number of immune events (SARS-CoV-2 infection or COVID-19 vaccination): 104.7 international units (IU)/mL, 955.0 IU/mL, and 2290.9 IU/mL for one, two, and three immune events, respectively (p < 0.001). In adjusted multivariable linear regression models, anti-S1 and anti-N log10 concentrations were significantly associated with infection severity, and anti-S1 log10 concentration with COVID-19 vaccine type/dose. In univariable models, anti-N log10 concentration was also significantly associated with acute infection duration, and severity and duration of individual symptoms. Antibody concentrations were not associated with long COVID or long-term loss of smell/taste. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. The epidemiological impact of digital and manual contact tracing on the SARS-CoV-2 epidemic in the Netherlands: Empirical evidence

Author

Ter Haar, Wianne, primary, Bosdriesz, Jizzo, additional, Venekamp, Roderick P., additional, Schuit, Ewoud, additional, van den Hof, Susan, additional, Ebbers, Wolfgang, additional, Kretzschmar, Mirjam, additional, Kluijtmans, Jan, additional, Moons, Carl, additional, Schim van der Loeff, Maarten, additional, Matser, Amy, additional, and van de Wijgert, Janneke H. H. M., additional

Published
2023
Full Text
View/download PDF

17. Genital tract infections, the vaginal microbiome and gestational age at birth among pregnant women in South Africa: a cohort study protocol

Author

Gigi, Ranjana M S, primary, Mdingi, Mandisa M, additional, Jung, Hyunsul, additional, Claassen-Weitz, Shantelle, additional, Bütikofer, Lukas, additional, Klausner, Jeffrey D, additional, Muzny, Christina A, additional, Taylor, Christopher M, additional, van de Wijgert, Janneke H H M, additional, Peters, Remco P H, additional, and Low, Nicola, additional

Published
2023
Full Text
View/download PDF

23. BCG Vaccination of Health Care Workers Does Not Reduce SARS-CoV-2 Infections nor Infection Severity or Duration: a Randomized Placebo-Controlled Trial

Author

Claus, Juana, primary, ten Doesschate, Thijs, additional, Gumbs, Cheyenne, additional, van Werkhoven, Cornelis H., additional, van der Vaart, Thomas W., additional, Janssen, Axel B., additional, Smits, Gaby, additional, van Binnendijk, Rob, additional, van der Klis, Fiona, additional, van Baarle, Debbie, additional, Paganelli, Fernanda L., additional, Leavis, Helen, additional, Verhagen, Lilly M., additional, Joosten, Simone A., additional, Bonten, Marc J. M., additional, Netea, Mihai G., additional, van de Wijgert, Janneke H. H. M., additional, Boersma, Wim G., additional, Bulut, Özlem, additional, van Crevel, Reinout, additional, Debisarun, Priya A., additional, Hoogerwerf, Jacobien, additional, de Jonge, Marien, additional, Kerckhoffs, Angele P. M., additional, Knol, Edward, additional, Koopman, Jan Pieter R., additional, Kuiper, Vincent P., additional, Lalmohamed, Arief, additional, Moorlag, Simone J. C. F. M., additional, Nierkens, Stefan, additional, van Nieuwkoop, Cees, additional, 10 Oever, Jaap, additional, Ottenhoff, Tom H. M., additional, Paternotte, Nienke, additional, Rijnders, Bart J. A., additional, Roukens, Anna H. E., additional, Taks, Esther, additional, Top, Janetta, additional, Veerman, Karin M., additional, Voss, Andreas, additional, and Willems, Rob, additional

Published
2023
Full Text
View/download PDF

24. Genital tract infections, the vaginal microbiome and gestational age at birth among pregnant women in South Africa: a cohort study protocol

Author

Epi Infectieziekten Team 1b, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Gigi, Ranjana M S, Mdingi, Mandisa M, Jung, Hyunsul, Claassen-Weitz, Shantelle, Bütikofer, Lukas, Klausner, Jeffrey D, Muzny, Christina A, Taylor, Christopher M, van de Wijgert, Janneke H H M, Peters, Remco P H, Low, Nicola, Epi Infectieziekten Team 1b, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Gigi, Ranjana M S, Mdingi, Mandisa M, Jung, Hyunsul, Claassen-Weitz, Shantelle, Bütikofer, Lukas, Klausner, Jeffrey D, Muzny, Christina A, Taylor, Christopher M, van de Wijgert, Janneke H H M, Peters, Remco P H, and Low, Nicola

Published
2023

25. The epidemiological impact of digital and manual contact tracing on the SARS-CoV-2 epidemic in the Netherlands: Empirical evidence

Author

HAG Onderzoek, Child Health, Infection & Immunity, Epi Methoden Team 2, Cancer, JC onderzoeksprogramma Methodologie, Epi Infectieziekten Team 2, JC onderzoeksprogramma Infectieziekten, Medische Microbiologie, Julius Centrum, Epi Infectieziekten Team 1b, Ter Haar, Wianne, Bosdriesz, Jizzo, Venekamp, Roderick P, Schuit, Ewoud, van den Hof, Susan, Ebbers, Wolfgang, Kretzschmar, Mirjam, Kluijtmans, Jan, Moons, Carl, Schim van der Loeff, Maarten, Matser, Amy, van de Wijgert, Janneke H H M, HAG Onderzoek, Child Health, Infection & Immunity, Epi Methoden Team 2, Cancer, JC onderzoeksprogramma Methodologie, Epi Infectieziekten Team 2, JC onderzoeksprogramma Infectieziekten, Medische Microbiologie, Julius Centrum, Epi Infectieziekten Team 1b, Ter Haar, Wianne, Bosdriesz, Jizzo, Venekamp, Roderick P, Schuit, Ewoud, van den Hof, Susan, Ebbers, Wolfgang, Kretzschmar, Mirjam, Kluijtmans, Jan, Moons, Carl, Schim van der Loeff, Maarten, Matser, Amy, and van de Wijgert, Janneke H H M

Published
2023

26. The impact of Bacillus Calmette-Guérin vaccination on antibody response after COVID-19 vaccination

Author

Epi Infectieziekten Team 1, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, Epi Infectieziekten Team 1b, Taks, Esther J M, Moorlag, Simone J C F M, Föhse, Konstantin, Simonetti, Elles, van der Gaast-de Jongh, Christa E, van Werkhoven, Cornelis H, Bonten, Marc J M, Oever, Jaap Ten, de Jonge, Marien I, van de Wijgert, Janneke H H M, Netea, Mihai G, Epi Infectieziekten Team 1, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Epi Infectieziekten, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, Epi Infectieziekten Team 1b, Taks, Esther J M, Moorlag, Simone J C F M, Föhse, Konstantin, Simonetti, Elles, van der Gaast-de Jongh, Christa E, van Werkhoven, Cornelis H, Bonten, Marc J M, Oever, Jaap Ten, de Jonge, Marien I, van de Wijgert, Janneke H H M, and Netea, Mihai G

Published
2023

27. Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study

Author

Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Epi Infectieziekten Team 1b, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Huiberts, Anne J, de Gier, Brechje, Hoeve, Christina E, de Melker, Hester E, Hahné, Susan J M, den Hartog, Gerco, Grobbee, Diederick E, van de Wijgert, Janneke H H M, van den Hof, Susan, Knol, Mirjam J, Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Epi Infectieziekten Team 1b, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Huiberts, Anne J, de Gier, Brechje, Hoeve, Christina E, de Melker, Hester E, Hahné, Susan J M, den Hartog, Gerco, Grobbee, Diederick E, van de Wijgert, Janneke H H M, van den Hof, Susan, and Knol, Mirjam J

Published
2023

28. Vulvovaginal yeast infections during pregnancy and perinatal outcomes: systematic review and meta-analysis

Author

Epi Infectieziekten Team 1b, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Gigi, Ranjana M S, Buitrago-Garcia, Diana, Taghavi, Katayoun, Dunaiski, Cara-Mia, van de Wijgert, Janneke H H M, Peters, Remco P H, Low, Nicola, Epi Infectieziekten Team 1b, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Gigi, Ranjana M S, Buitrago-Garcia, Diana, Taghavi, Katayoun, Dunaiski, Cara-Mia, van de Wijgert, Janneke H H M, Peters, Remco P H, and Low, Nicola

Published
2023

29. BCG Vaccination of Health Care Workers Does Not Reduce SARS-CoV-2 Infections nor Infection Severity or Duration: a Randomized Placebo-Controlled Trial

Author

Claus, Juana, Ten Doesschate, Thijs, Gumbs, Cheyenne, van Werkhoven, Cornelis H, van der Vaart, Thomas W, Janssen, Axel B, Smits, Gaby, van Binnendijk, Rob, van der Klis, Fiona, van Baarle, Debbie, Paganelli, Fernanda L, Leavis, Helen, Verhagen, Lilly M, Joosten, Simone A, Bonten, Marc J M, Netea, Mihai G, and van de Wijgert, Janneke H H M

Subjects
randomized placebo-controlled clinical trial, Bacillus Calmette-Guerin vaccine, SARS-CoV-2, COVID-19, health care workers
Abstract

Bacillus Calmette-Guerin (BCG) vaccination has been hypothesized to reduce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, severity, and/or duration via trained immunity induction. Health care workers (HCWs) in nine Dutch hospitals were randomized to BCG or placebo vaccination (1:1) in March and April 2020 and followed for 1 year. They reported daily symptoms, SARS-CoV-2 test results, and health care-seeking behavior via a smartphone application, and they donated blood for SARS-CoV-2 serology at two time points. A total of 1,511 HCWs were randomized and 1,309 analyzed (665 BCG and 644 placebo). Of the 298 infections detected during the trial, 74 were detected by serology only. The SARS-CoV-2 incidence rates were 0.25 and 0.26 per person-year in the BCG and placebo groups, respectively (incidence rate ratio, 0.95; 95% confidence interval, 0.76 to 1.21; P = 0.732). Only three participants required hospitalization for SARS-CoV-2. The proportions of participants with asymptomatic, mild, or moderate infections and the mean infection durations did not differ between randomization groups. In addition, unadjusted and adjusted logistic regression and Cox proportional hazards models showed no differences between BCG and placebo vaccination for any of these outcomes. The percentage of participants with seroconversion (7.8% versus 2.8%; P = 0.006) and mean SARS-CoV-2 anti-S1 antibody concentration (13.1 versus 4.3 IU/mL; P = 0.023) were higher in the BCG than placebo group at 3 months but not at 6 or 12 months postvaccination. BCG vaccination of HCWs did not reduce SARS-CoV-2 infections nor infection duration or severity (ranging from asymptomatic to moderate). In the first 3 months after vaccination, BCG vaccination may enhance SARS-CoV-2 antibody production during SARS-CoV-2 infection. IMPORTANCE While several BCG trials in adults were conducted during the 2019 coronavirus disease epidemic, our data set is the most comprehensive to date, because we included serologically confirmed infections in addition to self-reported positive SARS-CoV-2 test results. We also collected data on symptoms for every day during the 1-year follow-up period, which enabled us to characterize infections in detail. We found that BCG vaccination did not reduce SARS-CoV-2 infections nor infection duration or severity but may have enhanced SARS-CoV-2 antibody production during SARS-CoV-2 infection in the first 3 months after vaccination. These results are in agreement with other BCG trials that reported negative results (but did not use serological endpoints), except for two trials in Greece and India that reported positive results but had few endpoints and included endpoints that were not laboratory confirmed. The enhanced antibody production is in agreement with prior mechanistic studies but did not translate into protection from SARS-CoV-2 infection.

Published
2023

30. Diagnostic accuracy of covid-19 rapid antigen tests with unsupervised self-sampling in people with symptoms in the omicron period: cross sectional study

Author

Schuit, Ewoud, primary, Venekamp, Roderick P, additional, Hooft, Lotty, additional, Veldhuijzen, Irene K, additional, van den Bijllaardt, Wouter, additional, Pas, Suzan D, additional, Zwart, Vivian F, additional, Lodder, Esther B, additional, Hellwich, Marloes, additional, Koppelman, Marco, additional, Molenkamp, Richard, additional, Wijers, Constantijn J H, additional, Vroom, Irene H, additional, Smeets, Leonard C, additional, Nagel-Imming, Carla R S, additional, Han, Wanda G H, additional, van den Hof, Susan, additional, Kluytmans, Jan A J W, additional, van de Wijgert, Janneke H H M, additional, and Moons, Karel G M, additional

Published
2022
Full Text
View/download PDF

31. Factors Associated With Using the COVID-19 Mobile Contact-Tracing App Among Individuals Diagnosed With SARS-CoV-2 in Amsterdam, the Netherlands: Observational Study

Author

Ritsema, Feiko, primary, Bosdriesz, Jizzo R, additional, Leenstra, Tjalling, additional, Petrignani, Mariska W F, additional, Coyer, Liza, additional, Schreijer, Anja J M, additional, van Duijnhoven, Yvonne T H P, additional, van de Wijgert, Janneke H H M, additional, Schim van der Loeff, Maarten F, additional, and Matser, Amy, additional

Published
2022
Full Text
View/download PDF

32. Bacillus Calmette-Guérin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial

Author

Ten Doesschate, Thijs, van der Vaart, Thomas W, Debisarun, Priya A, Taks, Esther, Moorlag, Simone J C F M, Paternotte, Nienke, Boersma, Wim G, Kuiper, Vincent P, Roukens, Anna H E, Rijnders, Bart J A, Voss, Andreas, Veerman, Karin M, Kerckhoffs, Angele P M, Oever, Jaap Ten, van Crevel, Reinout, van Nieuwkoop, Cees, Lalmohamed, Arief, van de Wijgert, Janneke H H M, Netea, Mihai G, Bonten, Marc J M, van Werkhoven, Cornelis H, Ten Doesschate, Thijs, van der Vaart, Thomas W, Debisarun, Priya A, Taks, Esther, Moorlag, Simone J C F M, Paternotte, Nienke, Boersma, Wim G, Kuiper, Vincent P, Roukens, Anna H E, Rijnders, Bart J A, Voss, Andreas, Veerman, Karin M, Kerckhoffs, Angele P M, Oever, Jaap Ten, van Crevel, Reinout, van Nieuwkoop, Cees, Lalmohamed, Arief, van de Wijgert, Janneke H H M, Netea, Mihai G, Bonten, Marc J M, and van Werkhoven, Cornelis H

Abstract

OBJECTIVES: The COVID-19 pandemic increases healthcare worker (HCW) absenteeism. The bacillus Calmette-Guérin (BCG) vaccine may provide non-specific protection against respiratory infections through enhancement of trained immunity. We investigated the impact of BCG vaccination on HCW absenteeism during the COVID-19 pandemic.METHODS: HCWs exposed to COVID-19 patients in nine Dutch hospitals were randomized to BCG vaccine or placebo in a 1:1 ratio, and followed for one year using a mobile phone application. The primary endpoint was the self-reported number of days of unplanned absenteeism for any reason. Secondary endpoints included documented COVID-19, acute respiratory symptoms or fever. This was an investigator-funded study, registered at ClinicalTrials.gov (NCT03987919).RESULTS: In March/April 2020, 1511 HCWs were enrolled. The median duration of follow-up was 357 person-days (interquartile range [IQR], 351 to 361). Unplanned absenteeism for any reason was observed in 2.8% of planned working days in the BCG group and 2.7% in the placebo group (adjusted relative risk 0.94; 95% credible interval, 0.78-1.15). Cumulative incidences of documented COVID-19 were 14.2% in the BCG and 15.2% in the placebo group (adjusted hazard ratio (aHR) 0.94; 95% confidence interval (CI), 0.72-1.24). First episodes of self-reported acute respiratory symptoms or fever occurred in 490 (66.2%) and 443 (60.2%) participants, respectively (aHR: 1.13; 95% CI, 0.99-1.28). Thirty-one serious adverse events were reported (13 after BCG, 18 after placebo), none considered related to study medication.CONCLUSIONS: During the COVID-19 pandemic, BCG-vaccination of HCW exposed to COVID-19 patients did not reduce unplanned absenteeism nor documented COVID-19.

Published
2022

33. Bacillus Calmette-Guérin vaccine to reduce healthcare worker absenteeism in COVID-19 pandemic, a randomized controlled trial

Author

Infection & Immunity, Epi Infectieziekten Team 1, JC onderzoeksprogramma Infectieziekten, Cancer, Apotheek O&O&O, Regenerative Medicine and Stem Cells, Child Health, Brain, Epi Infectieziekten Team 1b, Epi Infectieziekten, Doesschate, Thijs Ten, van der Vaart, Thomas W, Debisarun, Priya A, Taks, Esther, Moorlag, Simone J C F M, Paternotte, Nienke, Boersma, Wim G, Kuiper, Vincent P, Roukens, Anna H E, Rijnders, Bart J A, Voss, Andreas, Veerman, Karin M, Kerckhoffs, Angele P M, Oever, Jaap Ten, van Crevel, Reinout, van Nieuwkoop, Cees, Lalmohamed, Arief, van de Wijgert, Janneke H H M, Netea, Mihai G, Bonten, Marc J M, van Werkhoven, Cornelis W, Infection & Immunity, Epi Infectieziekten Team 1, JC onderzoeksprogramma Infectieziekten, Cancer, Apotheek O&O&O, Regenerative Medicine and Stem Cells, Child Health, Brain, Epi Infectieziekten Team 1b, Epi Infectieziekten, Doesschate, Thijs Ten, van der Vaart, Thomas W, Debisarun, Priya A, Taks, Esther, Moorlag, Simone J C F M, Paternotte, Nienke, Boersma, Wim G, Kuiper, Vincent P, Roukens, Anna H E, Rijnders, Bart J A, Voss, Andreas, Veerman, Karin M, Kerckhoffs, Angele P M, Oever, Jaap Ten, van Crevel, Reinout, van Nieuwkoop, Cees, Lalmohamed, Arief, van de Wijgert, Janneke H H M, Netea, Mihai G, Bonten, Marc J M, and van Werkhoven, Cornelis W

Published
2022

34. Urine and vaginal microbiota compositions of postmenopausal and premenopausal women differ regardless of recurrent urinary tract infection and renal transplant status

Author

Epi Infectieziekten Team 1b, Infection & Immunity, JC onderzoeksprogramma Infectious Diseases, Hugenholtz, Floor, van der Veer, Charlotte, Terpstra, Matty L, Borgdorff, Hanneke, van Houdt, Robin, Bruisten, Sylvia, Geerlings, Suzanne E, van de Wijgert, Janneke H H M, Epi Infectieziekten Team 1b, Infection & Immunity, JC onderzoeksprogramma Infectious Diseases, Hugenholtz, Floor, van der Veer, Charlotte, Terpstra, Matty L, Borgdorff, Hanneke, van Houdt, Robin, Bruisten, Sylvia, Geerlings, Suzanne E, and van de Wijgert, Janneke H H M

Published
2022

35. Detection of SARS-CoV-2 infection in the general population by three prevailing rapid antigen tests: cross-sectional diagnostic accuracy study

Author

HAG Onderzoek, Child Health, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Epi Methoden, Cancer, JC onderzoeksprogramma Methodologie, Epi Infectieziekten Team 1b, Epi Methoden Team 4, Venekamp, Roderick P, Veldhuijzen, Irene K, Moons, Karel G M, van den Bijllaardt, Wouter, Pas, Suzan D, Lodder, Esther B, Molenkamp, Richard, Igloi, Zsofi, Wijers, Constantijn, Dos Santos, Claudy Oliveira, Debast, Sylvia B, Bruins, Marjan J, Polad, Khaled, Nagel-Imming, Carla R S, Han, Wanda G H, van de Wijgert, Janneke H H M, van den Hof, Susan, Schuit, Ewoud, HAG Onderzoek, Child Health, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Epi Methoden, Cancer, JC onderzoeksprogramma Methodologie, Epi Infectieziekten Team 1b, Epi Methoden Team 4, Venekamp, Roderick P, Veldhuijzen, Irene K, Moons, Karel G M, van den Bijllaardt, Wouter, Pas, Suzan D, Lodder, Esther B, Molenkamp, Richard, Igloi, Zsofi, Wijers, Constantijn, Dos Santos, Claudy Oliveira, Debast, Sylvia B, Bruins, Marjan J, Polad, Khaled, Nagel-Imming, Carla R S, Han, Wanda G H, van de Wijgert, Janneke H H M, van den Hof, Susan, and Schuit, Ewoud

Published
2022

36. The relationship between hormonal contraception and cervical dysplasia/cancer controlling for human papillomavirus infection: a systematic review

Author

Epi Infectieziekten Team 1, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Anastasiou, Elle, McCarthy, Katharine J, Gollub, Erica L, Ralph, Lauren, van de Wijgert, Janneke H H M, Jones, Heidi E, Epi Infectieziekten Team 1, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Anastasiou, Elle, McCarthy, Katharine J, Gollub, Erica L, Ralph, Lauren, van de Wijgert, Janneke H H M, and Jones, Heidi E

Published
2022

39. Additional file 1 of Head-to-head comparison of the accuracy of saliva and nasal rapid antigen SARS-CoV-2 self-testing: cross-sectional study

Author

Schuit, Ewoud, Venekamp, Roderick P., Veldhuijzen, Irene K., van den Bijllaardt, Wouter, Pas, Suzan D., Stohr, Joep J. J. M., Lodder, Esther B., Hellwich, Marloes, Molenkamp, Richard, Igloi, Zsofia, Wijers, Constantijn, Vroom, Irene H., Nagel-Imming, Carla R. S., Han, Wanda G. H., Kluytmans, Jan A. J. W., van den Hof, Susan, van de Wijgert, Janneke H. H. M., and Moons, Karel G. M.

Abstract

Additional file 1: Material 1. Short questionnaire after performing both self-tests at home. Material 2. Short questionnaire provided 10 days after test site visit. Material 3. Specimen collection, SARS-CoV-2 diagnostic testing, and SARS-CoV-2 virus culture procedures. Table S1. 2x2 tables for primary and secondary analyses of the molecular reference test – saliva Ag-RDT comparison. Table S2. 2x2 tables for primary and secondary analyses of the molecular reference test – nasal Ag-RDT comparison. Table S3. Follow-up information of participants that were tested again within 10 days after the initial test. Fig. S1. Sensitivities with 95% confidence intervals of the Ag-RDT-molecular reference standard test comparisons at viral load cut-off for infectiousness. Fig. S2. Distribution of viral loads in participants with a positive molecular reference test, stratified by symptomatology at time of sampling. Fig. S3. Distribution of change scores in difficulty of taking a sample and difficulty of reading the test result when comparing difficulty ratings of the saliva Ag-RDT and the nasal Ag-RDT.

Published
2022
Full Text
View/download PDF

40. Additional file 1 of Detection of SARS-CoV-2 infection in the general population by three prevailing rapid antigen tests: cross-sectional diagnostic accuracy study

Author

Venekamp, Roderick P., Veldhuijzen, Irene K., Moons, Karel G. M., van den Bijllaardt, Wouter, Pas, Suzan D., Lodder, Esther B., Molenkamp, Richard, Igloi, Zsofi, Wijers, Constantijn, dos Santos, Claudy Oliveira, Debast, Sylvia B., Bruins, Marjan J., Polad, Khaled, Nagel-Imming, Carla R. S., Han, Wanda G. H., van de Wijgert, Janneke H. H. M., van den Hof, Susan, and Schuit, Ewoud

Abstract

Additional file 1 : Suppl. Table S1. Baseline characteristics of the study population included in the PanBio test with less invasive sampling technique evaluation. Suppl. Table S2. Diagnostic accuracy variables of PanBio-molecular reference standard test comparison with less invasive sampling. Values are percentages (95% confidence interval) unless stated otherwise. Suppl. Table S3. Diagnostic accuracy variables of additional secondary analyses of three rapid antigen tests, with different sampling methods. Values are percentages (95% confidence interval) unless stated otherwise. Suppl. Table S4. Two-by-two tables used in primary and secondary analysis to determine diagnostic accuracy parameters of the BD VeritorTM System by Becton Dickinson (���BD-Veritor���) using routine sampling (OP-N). Suppl. Table S5. Two-by-two tables used in primary and secondary analysis to determine diagnostic accuracy parameters of the Roche/SD Biosensor by Roche Diagnostics (���SD-Biosensor���) using routine sampling (NP). Suppl. Table S6. Two-by-two tables used in primary and secondary analysis to determine diagnostic accuracy parameters of the Roche/SD Biosensor by Roche Diagnostics (���SD-Biosensor���) using less invasive sampling (OP-N). Suppl. Table S7. Two-by-two tables used in primary and secondary analysis to determine diagnostic accuracy parameters of the PanBio by Abbot (���PanBio���) using routine sampling (NP). Suppl. Table S8. Two-by-two tables used in primary and secondary analysis to determine diagnostic accuracy parameters of the PanBio by Abbot (���PanBio���) using less invasive sampling (OP-N). Suppl. Table S9. GISAID data contributors acknowledgement table. Suppl. Material 1. Short questionnaire (translated from Dutch). Suppl. Material 2. Specimen collection, SARS-CoV-2 diagnostic testing, and SARS-CoV-2 virus culture procedures.

Published
2022
Full Text
View/download PDF

43. Accuracy and usability of saliva and nasal rapid antigen self-testing for detection of SARS-CoV-2 infection in the general population: a head-to-head comparison

Author

Schuit, Ewoud, primary, Venekamp, Roderick P, additional, Veldhuijzen, Irene K, additional, van den Bijllaardt, Wouter, additional, Pas, Suzan D, additional, Stohr, Joep J J M, additional, Lodder, Esther B, additional, Hellwich, Marloes, additional, Molenkamp, Richard, additional, Igloi, Zsofia, additional, Wijers, Constantijn, additional, Vroom, Irene H, additional, Nagel-Imming, Carla R S, additional, Han, Wanda G H, additional, Kluytmans, Jan AJW, additional, van den Hof, Susan, additional, van de Wijgert, Janneke H H M, additional, and Moons, Karel G M, additional

Published
2021
Full Text
View/download PDF

46. Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies

Author

Torrone, Elizabeth A., Morrison, Charles S., Chen, Pai-Lien, Kwok, Cynthia, Francis, Suzanna C., Hayes, Richard J., Looker, Katharine J., McCormack, Sheena, McGrath, Nuala, van de Wijgert, Janneke H. H. M., Watson-Jones, Deborah, Low, Nicola, and Gottlieb, Sami L.

Subjects
Sexually transmitted diseases -- Demographic aspects -- Prevention, Bacterial vaginosis -- Demographic aspects -- Prevention, Women's health, Biological sciences
Abstract

Background Estimates of sexually transmitted infection (STI) prevalence are essential for efforts to prevent and control STIs. Few large STI prevalence studies exist, especially for low- and middle-income countries (LMICs). Our primary objective was to estimate the prevalence of chlamydia, gonorrhea, trichomoniasis, syphilis, herpes simplex virus type 2 (HSV-2), and bacterial vaginosis (BV) among women in sub-Saharan Africa by age, region, and population type. Methods and findings We analyzed individual-level data from 18 HIV prevention studies (cohort studies and randomized controlled trials; conducted during 1993-2011), representing >37,000 women, that tested participants for [greater than or equal to]1 selected STIs or BV at baseline. We used a 2-stage meta-analysis to combine data. After calculating the proportion of participants with each infection and standard error by study, we used a random-effects model to obtain a summary mean prevalence of each infection and 95% confidence interval (CI) across ages, regions, and population types. Despite substantial study heterogeneity for some STIs/populations, several patterns emerged. Across the three primary region/population groups (South Africa community-based, Southern/Eastern Africa community-based, and Eastern Africa higher-risk), prevalence was higher among 15-24-year-old than 25-49-year-old women for all STIs except HSV-2. In general, higher-risk populations had greater prevalence of gonorrhea and syphilis than clinic/community-based populations. For chlamydia, prevalence among 15-24-year-olds was 10.3% (95% CI: 7.4%, 14.1%; I.sup.2 = 75.7%) among women specifically recruited from higher-risk settings for HIV in Eastern Africa and was 15.1% (95% CI: 12.7%, 17.8%; I.sup.2 = 82.3%) in South African clinic/community-based populations. Among clinic/community-based populations, prevalence was generally greater in South Africa than in Southern/Eastern Africa for most STIs; for gonorrhea, prevalence among 15-24-year-olds was 4.6% (95% CI: 3.3%, 6.4%; I.sup.2 = 82.8%) in South Africa and was 1.7% (95% CI: 1.2%, 2.6%; I.sup.2 = 55.2%) in Southern/Eastern Africa. Across the three primary region/population groups, HSV-2 and BV prevalence was high among 25-49-year-olds (ranging from 70% to 83% and 33% to 44%, respectively). The main study limitation is that the data are not from random samples of the target populations. Conclusions Combining data from 18 HIV prevention studies, our findings highlight important features of STI/BV epidemiology among sub-Saharan African women. This methodology can be used where routine STI surveillance is limited and offers a new approach to obtaining critical information on STI and BV prevalence in LMICs., Author(s): Elizabeth A. Torrone 1,*, Charles S. Morrison 2, Pai-Lien Chen 2, Cynthia Kwok 2, Suzanna C. Francis 3, Richard J. Hayes 3, Katharine J. Looker 4, Sheena McCormack 5, [...]

Published
2018
Full Text
View/download PDF

47. The vaginal microbiome and sexually transmitted infections are interlinked: Consequences for treatment and prevention

Author

van de Wijgert, Janneke H. H. M.

Subjects
Sexually transmitted diseases -- Prevention -- Care and treatment, Vagina -- Health aspects, Microbiota (Symbiotic organisms) -- Health aspects, Biological sciences
Abstract

Author(s): Janneke H. H. M. van de Wijgert 1,2,* The increased availability of high-throughput molecular testing since the turn of the century has revealed a more detailed picture of organisms [...]

Published
2017
Full Text
View/download PDF

48. Diagnostic accuracy of rapid antigen tests in asymptomatic and presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross sectional study

Author

Schuit, Ewoud, primary, Veldhuijzen, Irene K, additional, Venekamp, Roderick P, additional, van den Bijllaardt, Wouter, additional, Pas, Suzan D, additional, Lodder, Esther B, additional, Molenkamp, Richard, additional, GeurtsvanKessel, Corine H, additional, Velzing, Jans, additional, Huisman, Robin C, additional, Brouwer, Lieke, additional, Boelsums, Timo L, additional, Sips, Gregorius J, additional, Benschop, Kimberly S M, additional, Hooft, Lotty, additional, van de Wijgert, Janneke H H M, additional, van den Hof, Susan, additional, and Moons, Karel G M, additional

Published
2021
Full Text
View/download PDF

49. Additional file 2 of Interventions to control nosocomial transmission of SARS-CoV-2: a modelling study

Author

Pham, Thi Mui, Tahir, Hannan, van de Wijgert, Janneke H. H. M., Van der Roest, Bastiaan R., Ellerbroek, Pauline, Bonten, Marc J. M., Bootsma, Martin C. J., and Kretzschmar, Mirjam E.

Subjects
virus diseases
Abstract

Additional file 2: Supplementary results. (1) Additional results for the main analysis: Table S1. Outcome measures for baseline and intervention scenarios. Figure S1. Positivity rate of screening interventions for different prevalence ranges. Figure S2. Positivity rate of contact tracing interventions for different prevalence ranges. Figure S3. Proportion of detected nosocomial transmissions of the SARS-CoV-2 variant for each simulation scenario. Figure S4. Transmission route contributions for nosocomial transmissions of the SARS-CoV-2 variant for each simulation scenario. Figure S5. Proportion of transmissions from HCWs and from patients for each simulation scenarios. Figure S6. Proportion of nosocomial transmissions in COVID- and non-COVID wards for each simulation scenario. Figure S7. Proportion of transmissions during different infection states for each simulation scenario. (2) Results of sensitivity analyses: Figure S8. Effective reproduction numbers for the nosocomial spread of the SARS-CoV-2 variant for each simulation scenario assuming 50% effective PPE. Figure S9. Number of nosocomial transmissions of the SARS-CoV-2 variant for each simulation scenario assuming 50% effective PPE. Figure S10. Daily percentage of absent HCWs during the hospital epidemic for each simulation scenario assuming 50% effective PPE. Figure S11. Effective reproduction numbers for the nosocomial spread of the SARS-CoV-2 variant for each simulation scenario assuming 70% effective PPE. Figure S12. Number of nosocomial transmissions of the SARS-CoV-2 variant for each simulation scenario assuming 70% effective PPE. Figure S13. Daily percentage of absent HCWs during the hospital epidemic for each simulation scenario assuming 70% effective PPE. Figure S14. Effective reproduction numbers for the nosocomial spread of the SARS-CoV-2 variant for each simulation scenario assuming equal reproduction numbers for symptomatically and asymptomatically infected individuals R_S=1·95 and R_A=1·95. Figure S15. Number of nosocomial transmissions of the SARS-CoV-2 variant for each simulation scenario assuming equal reproduction numbers for symptomatically and asymptomatically infected individuals R_S=1·95 and R_A=1·95. Figure S16. Daily percentage of absent HCWs during the hospital epidemic for each simulation scenario assuming equal reproduction numbers for symptomatic and asymptomatic individuals R_S=1·95 and R_A=1·95. Figure S17. Effective reproduction numbers for each simulation scenario assuming reproduction numbers of the wild-type SARS-CoV-2 variant. Figure S18. Number of nosocomial transmissions of the SARS-CoV-2 variant for each simulation scenario assuming reproduction numbers of the wild-type SARS-CoV-2 variant. Figure S19. Daily percentage of absent HCWs during the hospital epidemic for each simulation scenario assuming reproduction numbers of the wild-type SARS-CoV-2 variant. Figure S20. Effective reproduction numbers for the nosocomial spread of the SARS-CoV-2 variant for each simulation scenario assuming higher contact rates between HCWs. Figure S21. Number of nosocomial transmissions of the SARS-CoV-2 variant for each simulation scenario assuming higher contact rates between HCWs. Figure S22. Daily percentage of absent HCWs during the hospital epidemic for each simulation scenario assuming higher contact rates between HCWs. Figure S23. Effective reproduction numbers for the nosocomial spread of the SARS-CoV-2 variant for the high test sensitivity scenario. Figure S24. Number of nosocomial transmissions of the SARS-CoV-2 variant for each simulation scenario for the high test sensitivity scenario. Figure S25. Daily percentage of absent HCWs during the hospital epidemic for each simulation scenario for the high test sensitivity scenario. Figure S26. Effective reproduction numbers for the nosocomial spread of the SARS-CoV-2 variant for the low test sensitivity scenario. Figure S27. Number of nosocomial transmissions of the SARS-CoV-2 variant for each simulation scenario for the low test sensitivity scenario. Figure S28. Daily percentage of absent HCWs during the hospital epidemic for each simulation scenario for the low test sensitivity scenario. Figure S29. Effective reproduction numbers for the nosocomial spread of the SARS-CoV-2 variant for the recovery time sensitivity scenario. Figure S30. Number of nosocomial transmissions of the SARS-CoV-2 variant for each simulation scenario for the recovery time sensitivity scenario. Figure S31. Daily percentage of absent HCWs during the hospital epidemic for each simulation scenario for the recovery time sensitivity scenario.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results